Kazunori Shimoguchi
Nagasaki University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kazunori Shimoguchi.
Journal of Infection and Chemotherapy | 1995
Kazuhiro Tateda; Kenji Irifune; Kazunori Shimoguchi; Kazunori Tomono; Tetsuya Matsumoto; Mitsuo Kaku; Keizo Yamaguchi; Yoichi Hirakata
We investigated the influences of carrageenan, generally known to be a selective cytotoxic agent for macrophages, on the antibacterial host-defense systems such as the chemotactic responses to heat-killed bacteria or lipopolysaccharide in the pleural cavity and interleukin-1 production by pleural macrophages. Twenty-four hours after intraperitoneal injection of 200 mg/kg of carrageenan, there were no significant differences in the total and differential cell counts in lavaged fluid from the pleural cavity in carrageenan-pretreated and control mice. After intrapleural injection of heat-killedKlebsiella pneumoniae DT-S or lipopolysaccharide of this strain, significantly greater amounts of leukocytes, predominantly neutrophils, accumulated at 24 hrs in the pleural cavity of carrageenan-pretreated mice compared with control mice (P<0.05). Pleural macrophages obtained from carrageenan-pretreated mice produced more interleukin-1 in response to heat-killedK. pneumoniae DT-S or lipopolysaccharide than the control. Pretreatment with carrageenan significantly prolonged survival of mice against intrapleural challenge withK. pneumoniae DT-S. All 13 control mice died within 48 of inoculation with 9.2×106 organisms per mouse, whereas 11 of 13 carrageenan-pretreated mice survived (P<0.001). These results indicate that carrageenan pretreatment enhances the chemotactic responses to bacterial lipopolysaccharide in the pleural cavity and interleukin-1 production by pleural macrophages. In some experimental conditions, this polysaccharide may act as a macrophage priming agent, instead of macrophage blocker.
The Journal of the Japanese Association for Infectious Diseases | 1989
Keizo Yamaguchi; Kazuhiro Tateda; Kazunori Tomono; Yoichi Hirakata; Kazunori Shimoguchi; Toyohiro Sasaki; Kazuo Nouda; Kazuyuki Sugahara; Kaku M; Toshiaki Hayashi; Shigeru Kohno; Masaki Hirota; Kohei Hara; Nobuchika Kusano; Atsushi Saito; Yoshikazu Ishii
Investigation on the etiology of septicemia occurring among the immunocompromised patients was performed by using experimental model of the mouse with leukocytopenia. The ddY conventional mice of 4 weeks of age were inoculated with cyclophosphamide (CPM) intraperitoneally 3 to 5 times every other day with a dose of 3 mg/mouse once to make an agranulocytic status. Then, intraperitoneal administrations of various antibiotic regimens consisting of ampicillin (ABPC) alone, ABPC + ceftazidime (CAZ), ABPC + CAZ + cloxacillin (MCIPC), ABPC + CAZ + MCIPC + minocycline (MINO) and saline as a control to these immunosuppressed mice were begun once every day for 10 days after the second inoculation of CPM. The mortality rate of the mice given saline as a control was very high with a frequency of 43.3% and there were significant differences between the saline group and another antibiotic groups other than ABPC (p less than 0.01). On the other hand, the mortality rate of the group given APBC showed the highest rate of 70% and it was significantly higher than that of the saline control group (p less than 0.05). The main cause of most of the dead mice was septicemia due to P. aeruginosa and which were isolated from the feces of all these mice and serotype of the strains isolated from the heart blood and feces in the same host corresponded to each other. Moreover, intestinal bacterial flora in mice treated by saline and ABPC which highly showed Pseudomonas sepsis, was occupied dominantly by P. aeruginosa, although P. aeruginosa was not detectable from the experimental environments.(ABSTRACT TRUNCATED AT 250 WORDS)
The Journal of the Japanese Association for Infectious Diseases | 1994
Kenji Irifune; Kazunori Shimoguchi; Tamotsu Ishida; Mitsuo Kaku; Hironobu Koga; Shigeru Kohno; Kohei Hara
Archive | 1994
Tamotsu Ishida; Kazunori Shimoguchi; Junko Ohtake; Nobuo Morikawa; Mitsuo Kaku; Hironobu Koga
The Journal of the Japanese Association for Infectious Diseases | 1992
Kazuhiro Tateda; Goto S; Yoichi Hirakata; Yamaguchi K; Tetsuro Matsumoto; Nobuhiko Furuya; Kazunori Shimoguchi; Kenji Irifune; Kaku M; Shigeru Kohno
Japanese Journal of Hospital Pharmacy | 1992
Yoshikazu Ishii; Mitsuo Kaku; Kazunori Shimoguchi; Yukie Yasumura; Masataka Ichikawa; Toshiaki Usui
The Journal of the Japanese Association for Infectious Diseases | 1990
Kazunori Shimoguchi
Chemotherapy | 1990
K. Tateda; Keizo Yamaguchi; Yoshikazu Ishii; Kazunori Shimoguchi; Nobuchika Kusano; Kazuyuki Sugahara; Toshiaki Usui; Shigeru Kohno; Kohei Hara
The Journal of the Japanese Association for Infectious Diseases | 1989
Yoichi Hirakata; Keizo Yamaguchi; Kazunori Tomono; Kazunori Shimoguchi; Kazuhiro Tateda; Nouda K; Kazuyuki Sugahara; Shigeru Kohno; Masaki Hirota; Kohei Hara
The Journal of the Japanese Association for Infectious Diseases | 1989
Keizo Yamaguchi; Kazuhiro Tateda; Kazunori Tomono; Yoichi Hirakata; Nouda K; Kazunori Shimoguchi; Toyohiro Sasaki; Kazuyuki Sugahara; Kaku M; Toshiaki Hayashi